BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 3, 2019--
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare
company, today announced that the company will participate in the 37th
Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Robert
G. Finizio will provide an overview of the company at the conference.
Details for the presentation include:
Conference
|
|
37th Annual J.P. Morgan Healthcare Conference
|
Date
|
|
Wednesday, January 9, 2019
|
Time
|
|
1:30 p.m. PT
|
A live webcast and replay of the presentation can be accessed on the
company’s website, www.therapeuticsmd.com,
on the Home Page or under the “Investors & Media” section.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing novel products exclusively for women. Our
products are designed to address the unique changes and challenges women
experience through the various stages of their lives with a therapeutic
focus in family planning, reproductive health, and menopause management.
The company is committed to advancing the health of women and
championing awareness of their healthcare issues. To learn more about
TherapeuticsMD, please visit www.therapeuticsmd.com
or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking
statements. Forward-looking statements may include, but are not limited
to, statements relating to TherapeuticsMD’s objectives, plans and
strategies as well as statements, other than historical facts, that
address activities, events or developments that the company intends,
expects, projects, believes or anticipates will or may occur in the
future. These statements are often characterized by terminology such as
“believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,”
“will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments made in
light of management’s experience and perception of historical trends,
current conditions, expected future developments and other factors
believed to be appropriate. Forward-looking statements in this press
release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a
result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties, many of which are outside of the company’s
control. Important factors that could cause actual results, developments
and business decisions to differ materially from forward-looking
statements are described in the sections titled “Risk Factors” in the
company’s filings with the Securities and Exchange Commission, including
its most recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as reports on Form 8-K, and include the following: the
company’s ability to maintain or increase sales of its products; the
company’s ability to develop and commercialize IMVEXXYTM,
ANNOVERATM, BIJUVATM and its hormone therapy drug
candidates and obtain additional financing necessary therefor; whether
the company will be able to comply with the covenants and conditions
under its term loan agreement; the potential of adverse side effects or
other safety risks that could adversely affect the commercialization of
the company’s current or future approved products or preclude the
approval of the company’s future drug candidates; the ability of
licensees of the company’s products to commercialize such licensed
products; the length, cost and uncertain results of future clinical
trials; the company’s reliance on third parties to conduct its
manufacturing, research and development and clinical trials; the
availability of reimbursement from government authorities and health
insurance companies for the company’s products; the impact of product
liability lawsuits; the influence of extensive and costly government
regulation; the volatility of the trading price of the company’s common
stock and the concentration of power in its stock ownership. PDF copies
of the company’s historical press releases and financial tables can be
viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005172/en/
Source: TherapeuticsMD, Inc.
Investor Contact
Nichol Ochsner,
Vice President
Investor Relations
561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com